State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, People's Republic of China.
Breast Cancer Res Treat. 2010 Nov;124(1):223-7. doi: 10.1007/s10549-010-0800-8. Epub 2010 Mar 5.
Breast cancer is one of the most common malignant tumors worldwide. Endothelial nitric oxide synthase (eNOS) plays a key role in breast cancer development. The associations between the two eNOS polymorphisms (E298D rs1799983, -786T>C rs2070744) and breast cancer risk are inconclusive. A meta-analysis was performed in this study. By searching Medline, ISI Web of Knowledge, ScienceDirect, EBSCO, CNKI, and SinoMed database, six case-control studies were collected for the eNOS E298D polymorphism (3,038 cases and 2,508 controls) and three case-control studies were eligible for the eNOS -786T>C polymorphism. Crude ORs with 95% CIs were used to assess the strength of association between the two eNOS polymorphisms and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Overall, significantly decreased risk was observed for E298D (for EE vs. DD: OR = 0.74, 95% CI = 0.59-0.94; for ED vs. DD: OR = 0.78, 95% CI = 0.61-0.98; for dominant model: OR = 0.77, 95% CI = 0.61-0.96) and -786T > C (for TT vs. CC: OR = 0.60, 95% CI = 0.42-0.86; for dominant model: OR = 0.66, 95% CI = 0.47-0.94). In the subgroup analysis by ethnicity, significant decreased risks were found for E298D (for EE vs. DD: OR = 0.75, 95% CI = 0.56-0.99) and -786T>C (for TT vs. CC: OR = 0.53, 95% CI = 0.35-0.81; for dominant model: OR = 0.61, 95% CI = 0.41-0.91; for recessive model: OR = 0.70, 95% CI = 0.55-0.91) among Caucasians; significant decreased risks were observed for E298D (for ED vs. DD: OR = 0.12, 95% CI = 0.02-0.96; for dominant model: OR = 0.13, 95% CI = 0.02-1.00) among Asians. In conclusion, this meta-analysis suggests that both eNOS E298D and -786T>C polymorphisms are associated with reduced breast cancer risk.
乳腺癌是全球最常见的恶性肿瘤之一。内皮型一氧化氮合酶（eNOS）在乳腺癌的发展中起着关键作用。两种 eNOS 多态性（E298D rs1799983、-786T>C rs2070744）与乳腺癌风险之间的关联尚无定论。本研究进行了荟萃分析。通过检索 Medline、ISI Web of Knowledge、ScienceDirect、EBSCO、CNKI 和 SinoMed 数据库，共收集了 6 项关于 eNOS E298D 多态性（3038 例病例和 2508 例对照）的病例对照研究，3 项关于 eNOS -786T>C 多态性的病例对照研究符合纳入标准。使用未经调整的 OR 值和 95%CI 来评估两种 eNOS 多态性与乳腺癌风险之间的关联强度。分别采用共显性模型、显性模型和隐性模型进行汇总 OR 值分析。总体而言，E298D 多态性（EE 与 DD：OR=0.74，95%CI=0.59-0.94；ED 与 DD：OR=0.78，95%CI=0.61-0.98；显性模型：OR=0.77，95%CI=0.61-0.96）和 -786T>C 多态性（TT 与 CC：OR=0.60，95%CI=0.42-0.86；显性模型：OR=0.66，95%CI=0.47-0.94）均与乳腺癌风险降低显著相关。在按种族进行的亚组分析中，E298D 多态性（EE 与 DD：OR=0.75，95%CI=0.56-0.99）和 -786T>C 多态性（TT 与 CC：OR=0.53，95%CI=0.35-0.81；显性模型：OR=0.61，95%CI=0.41-0.91；隐性模型：OR=0.70，95%CI=0.55-0.91）在高加索人群中与乳腺癌风险降低显著相关；E298D 多态性（ED 与 DD：OR=0.12，95%CI=0.02-0.96；显性模型：OR=0.13，95%CI=0.02-1.00）在亚洲人群中与乳腺癌风险降低显著相关。综上所述，本荟萃分析提示，eNOS E298D 和 -786T>C 多态性均与乳腺癌风险降低相关。
